Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Arena Reports Fourth Quarter Financial Results with Strong Liquidity Position and Maintained Pipeline Progress Over the Quarter
- Significant pipeline progress with potentially first- or best-in-class drug candidates - Strong cash position of $1.1 billion as of December 31, 2020 SAN DIEGO --(BUSINESS WIRE)--Feb. 23, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today provided a corporate update and reported financial
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Feb. 18, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on February 15, 2021 , the Compensation Committee of its Board of Directors granted to eleven new employees inducement stock options to purchase an aggregate of 33,885 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals to Release Fourth Quarter & Full-Year 2020 Financial Results and Provide Corporate Update on February 23
SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) will release its fourth quarter and full-year 2020 financial results and provide a corporate update on Tuesday, February 23, 2021 , after the close of the U.S. financial markets.
View HTML
Toggle Summary Arena Pharmaceuticals Announces Changes to Board of Directors
- Industry veteran Garry Neil , MD, named Board Chair - Nawal Ouzren, CEO of Sensorion named to Board SAN DIEGO --(BUSINESS WIRE)--Feb. 16, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced changes to the Company’s Board of Directors. Garry Neil , MD, has been appointed Chair of the
View HTML
Toggle Summary Arena Pharmaceuticals Completes Full Enrollment of Etrasimod Phase 3 ELEVATE UC 52 Trial
– Evaluating 2 mg etrasimod in study participants with moderately-to-severely active ulcerative colitis (UC) – Topline data from ELEVATE UC 12 and UC 52 trials remain on track for Q1 2022 – Significant unmet need for safe and effective oral therapies in UC for patients with inadequate response,
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO --(BUSINESS WIRE)--Jan. 22, 2021-- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on January 15, 2021 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 16,950 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference on January 13
SAN DIEGO , Dec. 22, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that Amit D. Munshi , the Company's President and Chief Executive Officer, is scheduled to present virtually at the 39th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 , at
View HTML
Toggle Summary Arena Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO , Dec. 18, 2020 /PRNewswire/ --  Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that on December 15, 2020 , the Compensation Committee of its Board of Directors granted to five new employees inducement stock options to purchase an aggregate of 141,975 shares of its common
View HTML
Toggle Summary Arena Pharmaceuticals to Present Data from the Phase 2b ADVISE Trial - Late-Breaker at Revolutionizing Atopic Dermatitis Conference
- Data selected for late-breaker oral presentation on December 14 - Novel mechanism of action evaluated in moderate-to-severe atopic dermatitis (AD) - Significant unmet need exists for a safe, once-daily, oral therapy in AD SAN DIEGO , Dec. 11, 2020 /PRNewswire/ -- Arena Pharmaceuticals, Inc.
View HTML
Toggle Summary Arena Pharmaceuticals Achieves Target Enrollment for Etrasimod Phase 3 ELEVATE UC 52 Trial
- Evaluating 2 mg etrasimod in study participants with moderately to severely active ulcerative colitis (UC) - Topline data from ELEVATE UC 12 and UC 52 trials on track for Q1 2022 - Due to the high number of participants currently in screening queue, screening to continue for an additional three
View HTML